The Effect of Interferon-Beta Therapy on T-Helper 17/miR-326 and T-Helper 1/miR-29b-3p Axis in Relapsing-Remitting Multiple Sclerosis Patients

Background: We aimed to evaluate the therapeutic effects of interferon-beta (IFN-beta) on hsa-miR29b-3p and hsa-miR326 in isolated T-helper (Th)1 and Th17 cells expressed by relapsing-remitting multiple sclerosis (RRMS) patients before and after 1 year of treatment with IFN-beta. Methods: The study was done on 19 RRMS patients pre- and posttreatment with IFN-beta to evaluate the frequency of Th1 and Th17 cells by flow cytometry. The expression level of hsa-miR-29b-3p and hsa-miR-326 in isolated Th1 and Th17 cells was assessed by quantitative polymerase chain reaction. Enzyme-linked immunosorbent assay was also used to measure the plasma levels of I interferon -gamma and interleukin (IL)-17A. Results: Th17 cells and plasma levels of IL-17A decreased in RRMS patients after IFN-beta therapy but hsa-miR-29b-3p and hsa-miR-326 expression had no significant change in treated RRMS patients versus baseline. MxA gene expression was significantly induced upon IFN-beta therapy in patients with RRMS. Conclusion: IFN-beta therapy is more effective on Th17 than Th1, but it does not reform altered expression of hsa-miR-326 and hsa-miR-29b-3p in Th17 and Th1, respectively.

Automated summary

The study showed that IFN-beta therapy was more effective on Th17 cells in RRMS patients, but did not significantly affect the expression of hsa-miR-326 and hsa-miR-29b-3p.